Posts tagged “Biotech & Life Science”
Bayer CropScience on Tuesday unveiled the 6,000-square-foot building to promote honey bee health and well-being through public education exhibits for visitors, a conference room and a research lab. The vision is to have students mingle with company scientists and other bee experts to study ways to reverse the decline in the important pollinators' populations.
The Obama administration's timeline for having ready the new health care law's online sign-up system "was just flat out wrong," outgoing Health and Human Services Secretary Kathleen Sebelius said in an interview that aired Sunday.
WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.
Renowned physician Dr. Russell Greenfield - a regular contributor to The Dr. Oz Show and an author - has been named the new medical director for PurThread in North Carolina.
Drug giant GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.
The Durham drug-development company was expected to go public last week, but those plans were delayed. Now, two Wall Street news sites offer different possibilities for the IPO.
The Durham drug-development company was expected to go public this week, but those plans seem to have changed.
The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. The nasdaq says the IPO is expected to begin at some point today after trading opens. However, the share price is well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.
The RTP-based medical device firm is moving ahead with plans to raise as much as $100 million through a stock offering. A new filing with the SEC shows that shares will become available today. The capital raising effort is the latest in a series of moves by TransEnterix to grow the company and to raise funding for a new robotic surgery device.
The Durham-based drug firm has finalized plans to begin selling shares between $7 and $8 on Thursday on the Nasdaq under the symbol SCYX. That's well under an earlier targeted range of between $12 and $14 a share. Scynexis also is doubling the number of shares available.
Baxter International is acquiring Chapel Hill-based Chatham Therapeutics to gain control of gene-based therapy technology focused on hemophilia. The deal includes a $70 million upfront payment. Additional payments could be made based on development, regulatory and commercial milestones.
From humble beginnings as a startup at the LaunchBox Digital accelerator in 2011 to receiving an NC IDEA grant to winning a six-figure prize in an Allscripts challenge to $2.5 million in venture capital: That's the quick growth story of Chapel Hill's Keona Health, which aims to change how medical practices deal initially with patients.
After disclosing its latest update to the FDA about the company's robotic surgery technology, RTP-based TransEnterix moves to raise its profile. It also has plans to raise as much as $100 million in capital.
Jonathon Lawrie has re-joined the North Carolina Biotechnology Center as executive director of the Western Office in Asheville, as a result of Dale Carroll's decision to leave the post to become CEO of a newly formed regional economic development organization.
The Durham-based drug firm has finalized plans to begin selling shares between $12 and $14 on Thursday on the Nasdaq under the symbol SCYX. The company does not yet have a drug on the market and lost some $30 million in 2013.